Duality Advisers, LP Pacira Bio Sciences, Inc. Transaction History

Duality Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$27.7 - $35.48 $16,758 - $21,465	605 Added 1.77%	34,784 $1.02 Million
Q4 2023 Feb 01, 2024	BUY	$26.32 - $34.31 $41,875 - $54,587	1,591 Added 4.88%	34,179 $1.15 Million
Q3 2023 Nov 02, 2023	BUY	$30.68 - $40.09 $160,793 - $210,111	5,241 Added 19.16%	32,588 $999,000
Q2 2023 Jul 31, 2023	BUY	$36.12 - $47.5 $987,773 - $1.3 Million	27,347 New	27,347 $1.1 Million
Q4 2022 Feb 07, 2023	BUY	$38.19 - $57.45 $540,923 - $813,721	14,164 New	14,164 $546,000
Q4 2021 Feb 02, 2022	SELL	$47.97 - $62.21 $479,700 - $622,100	-10,000 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$54.64 - $61.3 $728,132 - $816,883	-13,326 Reduced 57.13%	10,000 $560,000
Q2 2021 Aug 09, 2021	BUY	$59.18 - $69.99 $1.38 Million - $1.63 Million	23,326 New	23,326 $1.42 Million
Q1 2021 May 13, 2021	SELL	$59.31 - $78.82 $1.5 Million - $1.99 Million	-25,251 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$50.47 - $66.26 $1.27 Million - $1.67 Million	25,251 New	25,251 $1.51 Million

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.